Founder of Blueprint. I help companies stop sending emails nobody wants to read.
The problem with outbound isn't the message. It's the list. When you know WHO to target and WHY they need you right now, the message writes itself.
I built this system using government databases, public records, and 25 million job posts to find pain signals most companies miss. Predictable Revenue is dead. Data-driven intelligence is what works now.
Your GTM team is buying lists from ZoomInfo, adding "personalization" like mentioning a LinkedIn post, then blasting generic messages about features. Here's what it actually looks like:
The Typical Red Sail Technologies SDR Email:
Why this fails: The prospect is an expert. They've seen this template 1,000 times. There's zero indication you understand their specific situation. Delete.
Blueprint flips the approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them.
Stop: "I see you're hiring compliance people" (job postings - everyone sees this)
Start: "Your pharmacy license #PH-045891 expires March 18th - CVS Caremark terminated 14 Texas pharmacies in January for lapsed licenses" (state licensing database with specific record number and recent consequence)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use government data with dates, record numbers, facility addresses.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - analysis already done, deadlines already pulled, patterns already identified - whether they buy or not.
These messages demonstrate such precise understanding of the prospect's current situation that they feel genuinely seen. Every claim traces to a specific data source with verifiable evidence.
Identify pharmacies experiencing sudden spikes in prior authorization denials for specific drugs, correlate with recent PBM policy changes, and provide the exact updated criteria causing rejections along with affected patient lists.
PA denials directly impact patient medication access and pharmacy revenue. When denial rates spike suddenly, pharmacists know something changed but often don't know what. Connecting their specific denial pattern to the exact PBM policy change (with the drug name, date, and new requirements) proves you're monitoring their operational data and external policy shifts simultaneously. The offer to provide updated criteria and patient resubmission lists delivers immediate value.
This play requires prior authorization transaction data showing approval/denial outcomes by drug and date, cross-referenced with PBM formulary changes.
Combined with external PBM policy monitoring to attribute denial spikes to specific policy changes. This synthesis is unique to your platform.Show multi-location pharmacy chains which specific locations underperform on processing speed or error rates compared to their other locations AND to comparable chains, then control for regional labor costs to isolate whether the issue is process/training (fixable) vs hiring/budget constraint (requires different approach).
Chain operators know they have performance variance but often lack the data to pinpoint where and why. By showing them "Dallas is 40% slower than Houston AND you're paying 11% more in labor costs there, so this is a workflow issue not a staffing issue," you're providing actionable operational intelligence they can act on immediately. The regional wage context distinguishes you from generic benchmarking - it shows you understand their market realities.
This play requires prescription processing timestamp data by location combined with regional pharmacist wage data.
Combined with public wage benchmarks to isolate process inefficiency from market labor costs. This analysis requires multi-location operational data only you have.Identify pharmacies with repeated PA denials for a specific drug due to missing required documentation fields, provide the updated submission template, and offer a list of patients needing resubmission to recover lost revenue.
Pharmacy staff often don't realize when PBM documentation requirements change, leading to repeated denials for the same preventable reason. By showing them "67 of 73 Eliquis PAs were denied because your template is missing the new cardiovascular risk field," you're diagnosing a fixable process gap and offering the exact solution (updated template + patient resubmission list) to recover revenue immediately.
This play requires PA submission and outcome data showing denial reasons, combined with PBM policy change monitoring.
The ability to correlate denial patterns with policy changes and generate patient resubmission lists is proprietary to your platform.Alert 340B contract pharmacies when specific locations experience sudden claim rejection rate spikes tied to a particular covered entity's eligibility requirement changes, providing the exact updated contract documentation and affected claim lists by location.
340B contract pharmacies often serve multiple covered entities with different eligibility rules. When one covered entity updates requirements, pharmacies may not notice the change until claims start rejecting en masse. By showing them "4 of your locations show 31% rejection rates for CE-240891 starting December 10th - that covered entity changed eligibility rules December 1st," you're connecting their operational pain to a specific external policy change with exact locations and dates. This proves you're monitoring their 340B operations at a granular level.
This play requires access to 340B claims processing data showing rejection codes by pharmacy location, cross-referenced with covered entity contract changes.
Only platforms processing 340B claims at scale can detect these location-specific patterns and attribute them to covered entity policy changes.Alert multi-location pharmacy chains when one location's prescription processing time is significantly slower than their other locations, quantifying the excess labor cost impact to create urgency for workflow investigation.
Chain operators assume performance variance exists but rarely have specific data on where and how much. By showing them "Dallas takes 19 minutes longer per script than Houston/Austin, costing you 269 extra labor hours monthly," you're turning a vague inefficiency into a quantified operational problem with clear financial impact. The routing question makes it easy to respond.
This play requires prescription processing timestamp data showing fulfillment duration by pharmacy location.
Multi-location operational visibility is only available to pharmacy management platforms tracking workflow metrics across all locations.Identify pharmacies where the vast majority of PA denials concentrate in a single drug, indicating a systemic template or process issue that's fixable immediately once identified.
When 89% of denials are for one drug starting on a specific date, that's clearly not a broad operational problem - it's a specific policy change the pharmacy missed. The precision of "89% are Eliquis denials since January 6th" combined with "Express Scripts changed criteria January 3rd" makes the cause-and-effect obvious. The routing question ("Is someone updating your PA template?") makes it easy to forward internally.
This play requires PA outcome data showing denials by drug and insurer.
The ability to detect drug-specific denial spikes and attribute them to external policy changes requires both claims data and policy monitoring.Identify independent pharmacies with state licenses expiring within 90 days where the dominant PBM by volume has recently terminated other pharmacies in the same state for lapsed licenses, creating urgent compliance risk with quantified business impact.
License renewal is routine administrative work that's easy to deprioritize - until you lose your largest PBM contract. By showing them "Your license #PH-045891 expires March 18th - CVS Caremark terminated 14 Texas pharmacies in January for lapsed licenses and Caremark is your largest PBM by volume," you're connecting a routine task to a concrete recent consequence that affects their specific situation. The routing question makes forwarding easy.
Identify pharmacies where Part D network termination occurred 30-60 days after receiving an FDA Form 483 citing compliance failures, revealing the non-obvious connection between regulatory observations and network contract consequences.
Most pharmacies don't realize that Part D contracts include compliance observation clauses allowing network termination after FDA citations. By showing them "FDA cited you December 1st for DSCSA verification failures - your Part D network terminated January 15th (47 days later)," you're connecting two events they likely viewed as separate. The precision of dates and the citation type (DSCSA) makes this feel researched, not templated. The routing question acknowledges they're likely already working on it.
Show multi-location chains where one location's slower processing speed translates to quantified excess labor cost per prescription compared to their other locations, making the operational inefficiency financially tangible and urgent.
Chain operators care about operational variance, but they REALLY care when you quantify the cost. "Dallas costs $27 more in labor per script due to 19 minutes longer processing time" turns a process problem into a P&L problem. At 850 scripts weekly, "$22,950 monthly excess labor cost" creates immediate urgency. The routing question makes it easy to escalate internally.
This play requires prescription processing time data combined with regional pharmacist wage benchmarks.
The ability to translate processing time variance into location-specific labor cost impact requires both operational data and external wage context.Identify 340B contract pharmacies where only certain locations show high rejection rates for a specific covered entity starting on a precise date, indicating contract compliance issues isolated to those locations rather than network-wide problems.
340B operators managing multiple locations often struggle to pinpoint which locations have compliance issues with which covered entities. By showing them "Walnut Creek and Oakland show 31% rejection rates for CE-240891 since December 10th while Fremont and San Jose remain at 3%," you're isolating the problem to specific locations AND connecting it to a covered entity policy change on December 1st. This level of specificity proves you're monitoring their 340B operations granularly.
This play requires 340B claims data showing rejection patterns by covered entity and location.
The ability to detect location-specific compliance divergence and attribute it to covered entity policy changes is unique to 340B contract pharmacy platforms.Identify pharmacies where state license expiration coincides with new PBM network verification timeline requirements that were recently updated, creating a tight compliance window most pharmacies haven't noticed yet.
PBM networks frequently update their administrative requirements without loud announcements. By showing them "CVS Caremark changed Texas network rules February 1st requiring verification 45 days before expiration - your license expires March 18th (that's 46 days from today)," you're alerting them to a new requirement they likely missed combined with their specific license timeline. The 1-day buffer creates urgency while the yes/no question makes response easy.
Alert pharmacies with approaching license expiration by quantifying their prescription volume dependency on the PBM that recently terminated other pharmacies for license lapses, making the business impact concrete and urgent.
License renewal is routine until you connect it to revenue risk. By showing them "CVS Caremark terminated 14 Texas pharmacies in January for expired licenses - Caremark processes 42% of your prescription volume," you're quantifying exactly how much of their business depends on staying compliant with this one PBM. The concrete deliverable (verification form + instructions) makes the next step obvious.
Identify 340B contract pharmacies where claims volume dropped significantly across all locations simultaneously starting on a specific date, indicating a systematic processing issue rather than location-specific or market-driven decline.
A 22% volume drop across all locations starting on the exact same date (January 2nd) rules out coincidence or market factors - something systemic changed. By quantifying the exact volume drop (2,847 to 2,219 claims) and showing it's simultaneous across all 4 locations, you're diagnosing a likely technical or process issue they may not have noticed yet. The routing question acknowledges urgency without assuming you know the cause.
This play requires 340B claims transaction data showing volume trends by pharmacy location.
The ability to detect simultaneous volume drops across multiple locations indicates systematic issues only visible with centralized claims monitoring.Identify pharmacies where FDA Form 483 citing DSCSA compliance failures preceded Medicare Part D network termination by 45 days, showing the direct regulatory-to-commercial consequence chain with specific dates and citation types.
The 45-day timeline between FDA 483 and Part D termination is specific enough to prove causation, not correlation. By stating the exact compliance failure (DSCSA transaction record gaps) and both dates, you're showing you've done the research to connect their regulatory problem to their commercial consequence. The dual routing question (compliance response AND reinstatement) shows you understand both issues need parallel attention.
Old way: Spray generic messages at job titles. Hope someone replies.
New way: Use public data to find companies in specific painful situations. Then mirror that situation back to them with evidence.
Why this works: When you lead with "Your Dallas location averages 47 minutes per prescription vs 28 minutes at Houston - that's $27 extra labor cost per script" instead of "I see you're hiring for pharmacy roles," you're not another sales email. You're the person who did the homework.
The messages above aren't templates. They're examples of what happens when you combine real data sources with specific situations. Your team can replicate this using the data recipes in each play.
Every play traces back to verifiable data. Here are the sources used in this playbook:
| Source | Key Fields | Used For |
|---|---|---|
| NPPES NPI Registry | NPI, Provider Name, Provider Type, Practice Location Address, State, Taxonomy Code | Identifying pharmacy locations and verification |
| 340B OPAIS | Covered Entity Name, Contract Pharmacy Name, Pharmacy Address, Contract Status | Identifying 340B contract pharmacy relationships |
| CMS Medicare Part D Network Data | PDP Plan Name, Pharmacy Network Name, Network Pharmacy Count, NPI Numbers | Tracking network participation changes and terminations |
| FDA Inspections Dashboard | Inspection Date, Facility Name, Form 483 Observations, Compliance Status | Identifying pharmacies with compliance observations |
| Texas State Board of Pharmacy | Pharmacy License Number, Pharmacy Name, License Status, Expiration Date | Tracking license expiration timelines and compliance status |
| Bureau of Labor Statistics | Regional Pharmacist Wages, Pharmacy Technician Wages by Metro Area | Contextualizing labor costs for performance analysis |
| Internal: Claims Processing Data | Claim Volume, Approval/Denial Outcomes, Rejection Codes, Processing Time | Detecting denial patterns and operational inefficiencies |
| Internal: 340B Transaction Data | Claims Volume by Location, Covered Entity, Rejection Rates by Contract | Monitoring 340B contract pharmacy performance |